CLINICAL TRIALS PROFILE FOR ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR
✉ Email this page to a colleague
All Clinical Trials for Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04043806 ↗ | A Study Evaluating the Long-term Safety of VX-445 Combination Therapy | Active, not recruiting | Vertex Pharmaceuticals Incorporated | Phase 3 | 2019-08-09 | This study will evaluate the long-term safety and tolerability of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA). |
| NCT04058353 ↗ | A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) | Completed | Vertex Pharmaceuticals Incorporated | Phase 3 | 2019-08-28 | This study will evaluate the efficacy, safety and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a gating or residual function mutation (F/G and F/RF genotypes). |
| NCT04058366 ↗ | Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy | Active, not recruiting | Vertex Pharmaceuticals Incorporated | Phase 3 | 2019-12-05 | This study will evaluate the long-term safety, efficacy, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a gating or residual function mutation (F/G and F/RF genotypes). |
| NCT04105972 ↗ | A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del | Completed | Vertex Pharmaceuticals Incorporated | Phase 3 | 2019-10-03 | This study will evaluate the efficacy, safety, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous for F508del. |
| NCT04183790 ↗ | Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older | Active, not recruiting | Vertex Pharmaceuticals Incorporated | Phase 3 | 2020-02-17 | This study will evaluate the long-term safety, tolerability, efficacy, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor
Condition Name
| Condition Name for Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor | |
| Intervention | Trials |
| Cystic Fibrosis | 19 |
| Adherence, Medication | 1 |
| Cystic Fibrosis Gastrointestinal Disease | 1 |
| Cystic Fibrosis in Children | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor
Trials by Country
Clinical Trial Progress for Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor
Clinical Trial Phase
Clinical Trial Sponsors for Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor
Sponsor Name
